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Original Article
Comparison of Clinical Outcomes in
Patients Selected for Infra-Popliteal
Bypass or Plain Balloon Angioplasty
for Chronic Limb Threatening Ischemia
Between 2009 and 2013
Matthew A. Popplewell, MBChB, MRCS1 , Huw O. B. Davies, MBBS, BSc, MD, FRCS1,
Lewis Meecham, MBChB, MRCS1, Gareth Bate, RGN1, and
Andrew W. Bradbury, BSc, MB, ChB (Hons), MBA, MD, FEBVS, FRCSEd, FRCSEng1
Abstract
Introduction: A published subgroup analysis of the Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL)-1 trial
suggests that, in patients with chronic limb threatening ischemia (CLTI) due to infra-popliteal (IP) disease, clinical outcomes are
better following vein bypass surgery (BS) than after plain balloon angioplasty (PBA). The aim of the present study is to determine if
clinical outcomes following IP revascularization in our unit are concordant with those found in BASIL-1. Methods: We analyzed
prospectively gathered data pertaining to 137 consecutive CLTI patients undergoing IP PBA or BS between 2009 and 2013. We
compared 30-day morbidity and mortality, days in hospital (index admission and out to 12-months), amputation free survival
(AFS), overall survival (OS), limb salvage (LS), and freedom from arterial re-intervention (FFR). Patient outcomes were censored
on 1 February 2017, providing a minimum 3 years follow-up. Results: Patients undergoing BS (73/137, 47%) tended to be
younger, have less comorbidity, and were more likely to be on best medical therapy (BMT). BS patients spent more days in
hospital during the index admission (median 9 vs 5, p¼ .003), but not out to 12 months (median 15 vs 13, NS). BS patients suffered
more 30-day morbidity (36% vs 10%, p < .001), mainly due to infective complications, but not mortality (3.1% vs 6.8%, NS). AFS
(p¼ .001) and OS (p< .001), but not LS or FFR, were better after BS. Conclusions: CLTI patients selected for revascularization
by means of IP BS had better long-term outcomes in terms of AFS and OS, but not FFR or LS. Although we await the results of the
BASIL-2 trial, current data support the BASIL-1 sub-group analysis which suggests that patients requiring revascularization for IP
disease should have BS where possible and that PBA should usually be reserved for patients who are not suitable for BS.
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Introduction
Chronic limb threatening ischemia (CLTI) is a growing global
health and social care problem due to widespread tobacco use
and the increasing worldwide prevalence of diabetes.1,2 The
condition remains associated with very poor outcomes in terms
of major lower limb amputation (MLLA) and premature car-
diovascular and all-cause mortality. The evidence base under-
pinning the management of CLTI is limited, especially with
regard to revascularization strategies, and particularly with
regard to the infra-popliteal (IP) segment. The UK National
Institute of Health Research (NIHR) Health Technology
Assessment (HTA)-funded Bypass versus Angioplasty in
Severe Ischaemia of the Leg (BASIL)-1 remains the only pub-
lished randomized controlled trial (RCT) to have compared
infra-inguinal bypass surgery (BS) with plain balloon angio-
plasty (PBA) for CLTI.3
In 2017, we published a BASIL-1 IP sub-group analysis that
demonstrated a trend toward improved amputation free sur-
vival (AFS) and overall survival (OS) in those undergoing
BS, and showed that BS was associated with highly signifi-
cantly better quality of revascularization than PBA in terms of
relief of ischemic rest pain.4 However, the procedures were
performed between 1999 and 2003 leading to suggestions that
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BASIL-1 outcomes are no longer relevant to current endovas-
cular practice.
To further address the issue of preferred IP revascularization
strategies for CLTI, the UK NIHR HTA funded the BASIL-2
trial which compares IP vein BS with best endovascular treat-
ment (BET) in patients presenting with CLTI who require IP
revascularization.5 Although the BASIL-2 trial is likely to
complete recruitment in 2020, there then follows a minimum
of 2 years of follow-up, such that the final results are unlikely
to be published until early 2023. In the meantime, therefore,
there remains a large “gray area of clinical equipoise” regard-
ing IP revascularization strategies for CLTI.
The aim of the present study was to determine if important
clinical outcomes following IP revascularization in our unit
(2009-2013) are concordant with those found in BASIL-1
(2009-2013) and, further, to encourage participation in
BASIL-2.
Methods
This was a retrospective analysis of prospectively gathered
hospital data pertaining to 137 consecutive CLTI patients
selected for either IP PBA or BS in our unit between 1 June
2009 and 30 July 2013. Prior to revascularization, all patients
were discussed in a vascular multi-disciplinary meeting. Inter-
vention was planned based on the availability of venous con-
duit, patient fitness, patient choice and the technical options
following detailed imaging. We compared 30-day morbidity
and mortality, length of hospital stay (for both index admission
and out to 12-months), amputation free survival (AFS), overall
survival (OS), limb salvage (LS), and freedom from arterial re-
intervention (FFR). In addition to this, we compared AFS and
OS in those that survived the primary hospital episode with the
index limb intact.
As the data analyzed were collected as part of normal rou-
tine clinical practice, ethical approval was not sought in accor-
dance with advice from the UK National Research Ethics
Service (http://www.hra-decisiontools.org.uk/ethics/). Patient
outcomes were censored on 1 February 2017 so providing a
minimum of 3 years follow-up. Continuous data are reported
using mean or median values and compared using t-test or
Mann-Whitney U test, depending on the characteristics of data
distribution. Categorical data are compared using Fishers Exact
or Chi-squared test. Time to event data were analyzed using the
Kaplan-Meier method and log-rank statistics presented as a
hazard ratios (HR) and 95% confidence intervals (CI). Statis-
tical analysis was performed using R version 3.6.1 (2019-07-
05)© 2019. The R Foundation for Statistical Computing.
Graphical illustrations presented were prepared using Graph-
Pad Prism 8 software ver. 8.3.0, GraphPad Software, LLC©.
Results
Patients undergoing BS (64/137, 47%) tended to be younger
with less co-morbidity and were also more likely to be on best
medical therapy (BMT) (Table 1). Patients undergoing PBA
had a higher incidence of previous myocardial infarction (BS
10/64, 16% vs. PBA 29/73, 40%, p ¼ .004) and were more
likely to have diabetes (BS 27/64, 42% vs. PBA 45/73, 62%,
p ¼ .02). Although the number of patients with tissue loss in
both groups was similar, the PBA patients tended to have more
hindfoot involvement. A higher proportion of patients under-
going BS had undergone previous intervention in the index leg
(BS 24/64, 38% vs. PBA 16/73, 22%, p ¼ .04).
In those patients undergoing PBA, 4 also received a bare
metal stent (BMS). No drug coated balloons (DCB) or drug
eluting stents (DES) were used. Only 6 PBA patients had more
than one crural vessel treated (Table 2). Immediate technical
success (defined by the operator at the time of procedure) was
90%. In 4 cases it was not possible to cross the target lesion; 2
patients had distal embolism which resulted in loss of the target
vessel; and 1 patient had a residual stenosis that was not amen-
able to stenting.
The majority of patients undergoing BS had great saphenous
venous conduit (53/64, 83%) which was usually reversed
(Table 3). Prosthetic material was used in 9 patients (3 pros-
thetic and 6 composite-sequential grafts). Immediate technical
success was 97%; 2 procedures were abandoned as the target
Table 1. Baseline Characteristics.
BS (n ¼ 64) PBA (n ¼ 73) p value
Mean and SD age (years) 73.2 (11.2) 76.9 (10.2) 0.02




103.7 (112.5) 125.3 (123.4) NS
Stroke / Transient Ischemic
Attack (%)
13 (20%) 16 (22%) NS
Myocardial Infarction (%) 10 (16%) 29 (40%) 0.004
Angina (%) 17 (27%) 31 (42%) 0.05
End stage renal disease (%) 2 (3%) 7 (10%) NS
Diabetes Mellitus (%) 27 (42%) 45 (62%) 0.02
Insulin dependent Diabetes
Mellitus (%)
10/27 (37%) 17/45 (38%) NS
Clinical Presentation
Tissue loss (%) 44 (69%) 56 (77%) NS
Site of tissue loss (single patient may have multiple sites)
Hallux (%) 19 (30%) 24 (33%) NS
Other toes (%) 19 (30%) 21 (29%) NS
Forefoot (%) 6 (9%) 11 (15%) NS
Hindfoot (%) 1 (2%) 8 (11%) 0.03
Ankle (%) 3 (5%) 3 (4%) NS
Above ankle (%) 10 16%) 14 (19%) NS
Medical therapy
Antiplatelet agent (%) 55 (86%) 52 (71%) 0.04
Dual antiplatelet therapy (%) 8 (13%) 19 (26%) 0.04
Antihypertensive agent (%) 51 (80%) 58 (79%) NS
Statin therapy (%) 57 (89%) 50 (68%) 0.004
Anticoagulation (%) 13 (20%) 5 (7%) 0.02
Previous Intervention
Total (%) 24 (38%) 16 (22%) 0.04
Endovascular (%) 17 (27%) 11 (15%) NS
Surgical (%) 10 (17%) 3 (4%) 0.03
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crural vessel was judged unsuitable for bypass following sur-
gical exposure. In 5 patients, the bypass failed within 30 days.
Thirty-day mortality was non-significantly worse in patients
undergoing PBA (RR 2.19, 95% CI 0.44-10.91, 5 patients,
6.8% vs. 2 patients, 3.1% BS, NS). In both cohorts the most
common causes of death were pneumonia, sepsis from other
causes and cardiac disease (Table 4). Those selected for BS
suffered more 30-day morbidity (RR 3.75, 95% CI 1.72-8.15,
p < .001), mainly as a result of surgical site infection (SSI) and
other causes of sepsis (Table 5). BS patients spent more days in
hospital during the index admission (median 9 vs 5 days,
p¼ .003), but not out to 12 months (median 15 vs 13 days, NS).
AFS was significantly better in those selected for BS (HR
0.50, 95% CI 0.33-0.76, p ¼ .001, Figure 1). AFS after BS was
estimated at 69%, 58% and 56% at 1, 3 and 5 years respectively
and the mean AFS after BS was 4.6 (3.8 to 5.5, 95% CI) years.
AFS after PBA was estimated at 62%, 42% and 26% at the
same time points and the mean AFS after PBA was 2.8 (2.2 to
3.4, 95% CI) years.
OS was also significantly better in those selected for BS (HR
0.42, 95% CI 0.27-0.66, p < .001, Figure 2). OS following BS
was estimated at 80%, 71% and 69% at 1, 3 and 5 years respec-
tively, and the mean OS after BS was 5.6 (4.7 to 6.4, 95% CI)
years. OS following PBA was estimated at 75%, 52% and 34%
at the same time points, and the mean OS after PBA was 3.5
(2.9 to 4.1, 95% CI) years.
There was no significant difference in LS between BS and
PBA (HR 0.80, 95% CI 0.35-1.81, p ¼ .6, Figure 3). In the BS
group, 6 patients had transtibial and 4 had transfemoral ampu-
tations. In comparison, 7 of those undergoing PBA required
transtibial and 4 had transfemoral amputations.
There was no significant difference in FFR between BS and
PBA (HR 0.99, 95% CI 0.48-2.05, p ¼ 1.0, Figure 4). Eight
patients (12.5%) in the BS group required secondary bypass,
and 3 (4.7%) went on to have PBA. Seven of those undergoing
Table 2. PBA Treatment Details.
No. (n ¼ 73)
Arteries treated Superficial Femoral 27 (37%)
Above Knee Popliteal 25 (34%)
Below Knee Popliteal 33 (45%)
Tibio-peroneal Trunk 26 (36%)
Posterior Tibial 16 (22%)
Peroneal 18 (25%)
Anterior Tibial 27 (37%)
Dorsalis Pedis 1 (1%)
Number of IP vessels
treated
TPT most distal target 18 (25%)
1 vessel 49 (67%)
2 vessels 6 (8%)
3 vessels 0 (-)
Type of disease treated Occlusive 41 (56%)
Stenotic 50 (68%)
Combination 18 (25%)
Type of intervention PBA 70 (96%)
PBA þ bare metal stent 4 (5%)
Technical Failure Inability to cross lesion 4/7 (57%)





Total technical failure 7/73 (10%)
Table 3. BS Treatment Details.
No. (n ¼ 64)






Leg vein 46 (72%) Ipsilateral GSV
6 (9%) contralateralGSV
Arm vein 1 (2%)
Prosthetic 3 (5%)
Composite Sequential 6 (9%)
No bypass performed as




Common femoral artery 51 (80%)
Superficial femoral artery 5 (8%)









Tibioperoneal trunk 8 (12%)
Posterior tibial artery 1/3 16 (25%)
Posterior tibial artery 2/3 4 (6%)
Posterior tibial artery 3/3 6 (9%)
Peroneal artery 1/3 12 (19%)
Peroneal artery 2/3 0 (-)
Peroneal artery 3/3 2 (3%)
Anterior tibial artery 1/3 9 (14%)
Anterior tibial artery 2/3 2 (3%)
Anterior tibial artery 3/3 1 (2%)
Dorsalis pedis 2 (3%)
Technical
failures




Total technical failure 7/64 (11%)
Table 4. Cause of Death.
Cause BS (n ¼ 64) PBA (n ¼ 73) p value
Pneumonia/Respiratory 4 (6%) 10 (14%) NS
Sepsis (other causes) 2 (3%) 4 (5%) NS
Malignancy 2 (3%) 3 (4%) NS
Cardiac 3 (5%) 9 (12%) NS
Acute Kidney Injury 2 (3%) 0 (-) NS
Unknown 8 (13%) 16 (22%) NS
Stroke 2 (3%) 4 (5%) NS
Upper Gastrointestinal
bleeding
1 (2%) 0 (-) NS
“Old age” 0 (-) 2 (3%) NS
Intracranial bleed 0 (-) 2 (3%) NS
Venous thromboembolism 0 (-) 1 (1%) NS
Total 24/64 (38%) 51/73 (70%) <.001
Popplewell et al 3
PBA (9.6%) had repeat PBA, and 7 patients (9.6%) went on to
have BS.
Overall, 63 and 66 patients undergoing BS and PBA respec-
tively were discharged alive from our unit without undergoing
transtibial or transfemoral amputation. Of these patients, those
undergoing BS had significantly better AFS (HR 0.54, 95% CI
0.35-0.84, p ¼ .006) and OS (HR 0.46, 95% CI 0.29-0.74,
p ¼ .002) than those undergoing PBA.
Discussion
The main finding of the present study is that important clinical
outcomes following IP BS and PBA in a non-randomized con-
temporary series of patients treated in our unit between 2009
and 2013 are very similar, both in absolute and relative terms,
to those reported in patients recruited to the multi-centre
Table 5. Peri-Procedural (Thirty-Day) Morbidity.





















(2 CD II), 1CD V)
4 (5%)
(1 CD II, 3CD V)
NS











Total 23/64 (36%) 7/73 (10%) <.001
Abbreviations; CD, Clavien-Dindo.16
Figure 1. Amputation free survival. HR 0.50, 95% CI 0.33-0.77,
p ¼ .001.
Figure 2. Overall survival. HR 0.42, 95% CI 0.27-0.66, p < .001.
Figure 3. Limb salvage. HR 0.8, 95% CI 0.35-1.81, p ¼ .6.
Figure 4. Freedom from re-intervention. HR 0.99, 95% CI 0.48-2.05,
p ¼ 1.0.
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BASIL-1 RCT between 1999 and 2003. In our series, patients
undergoing BS did significantly better in terms of AFS and OS
than those receiving PBA. BASIL-1 reported similar outcomes
but to a smaller degree of significance than we present here.
Patients in this contemporary series (CS) selected for BS
were similar in terms of age and co-morbidity (previous cere-
brovascular disease, myocardial infarction, end stage renal dis-
ease [ESRD] and diabetes) to those patients in the BASIL-1 IP
subgroup (B1). However, those undergoing PBA tended to
have a higher burden of such co-morbidity.
One may argue that the number of IP revascularizations in a
50-month period is low, given the size of our vascular unit. In
the last decade we have seen a shift in the presentation of
disease. A prospective cohort study performed in our unit
between 2014 to 2018 to showed, disappointingly, that around
40% of patients who present with CLTI with significant IP
disease are either too unfit for any intervention, present with
a non-salvageable limb, or have pattern of disease that is not
amenable either endovascular intervention or BS. The reasons
for this are probably increasing burden of diabetes, ESRD, and
advancing age of the general and CLTI population.
In terms of BMT, the prescription of statins in the current
BS cohort had more than doubled when compared to the B1 BS
patients (B1 39% vs. CS 89%). In the B1 subgroup, 75% of
patients undergoing BS were prescribed an antiplatelet agent;
in the current BS cohort this was somewhat higher at 86%.
Although improved rates of statin prescription were also seen
in the current PBA cohort compared with the B1 PBA patients
(68% vs 25%), rates were still much lower than in those under-
going BS. Only 58% of patients undergoing PBA in the B1
cohort were prescribed an antiplatelet agent. Although this had
increased to 71% in our current cohort, this is still far from
optimal and may have contributed to the poorer outcomes in
this group. More rigorous follow up in the BS group (graft
surveillance) provides an additional opportunity to reinforce
the importance of BMT. Reduced outpatient contacts with the
patients undergoing PBA may explain the difference in statin
prescribing practice. The recorded increase in statin prescrip-
tion is likely due to an increased awareness of the importance
of BMT in the CLTI population. This was further reinforced in
2012 by the National Institute of Health and Care Excellence
(NICE) Clinical Guideline (CG 1457) on peripheral arterial
disease.6
Disappointingly, the majority of CLTI patients (>80%) still
present with tissue loss and this has remained unchanged since
B1. It is difficult to know if the extent of tissue loss was dif-
ferent between these groups as the Society for Vascular Sur-
gery (SVS) Wound Ischaemia Foot Infection (WIfI)7 tool was
not in use during either study period. However, patients in the
current PBA group tended to more tissue loss in the hindfoot,
which may have contributed to their overall poorer outcomes.
We have previously reported a comparison of outcomes in
the patients undergoing IP PBA in this cohort with similar
patients in the B1 subgroup.8 In that study we demonstrated
that, although patients were similar at baseline, patients under-
going IP intervention had a greater burden of FP disease in
patients from the B1 cohort. Although PBA technical success
was also somewhat better in our current IP cohort than B1, this
did not appear to translate into any longer-term clinical benefit
in terms of AFS or OS.
Immediate technical success rates have improved since
BASIL-1 for both BS (97% vs 86%) and PBA (90% vs.
73%). Our current technical success for patients undergoing
IP PBA is comparable to results published in the literature.9
This may be due to improved technologies, techniques and
better patient selection.
Following PBA, 7 patients (9.6%) went on to have salvage
vein BS. One may argue that this group of patients would have
been better served with primary vein BS. However, how this
would have affected outcomes is a matter of speculation. It is
hoped that the results of the BASIL-2 trial5 will aide decision
making in this group of patients.
Patients in our current series spent less time in hospital than
those a decade previously in B1. The length of index hospital
admission was almost 50% lower in our recent cohort when
compared to B1 (median BS 18 days vs. PBA 10 days) for both
the BS and PBA groups. B1 patients also spent longer in hos-
pital over the 12-months following intervention (a median of
over 40 days).
AFS in B1 was estimated at 36% for BS and 15% for PBA
out to 5 years. This was higher in our current series (BS 56% vs.
PBA 25%). Trends in OS significantly improved in those
undergoing BS (B1 49% vs. CS 68%) but not PBA (B1 28%
vs. CS 32%) at the same time point. Although this is likely to be
multifactorial, as discussed above, it may be due in part to the
better use of BMT seen in our current series. In those that
survived, LS (approximately 80%) and FFR (approximately
70%) were similar to that observed for both BS and PBA in B1.
Interestingly, after removing from the analysis those
patients that did not survive or underwent amputation during
the index hospital admission, the significant differences in
favor of BS in terms of AFS and OS remained unchanged.
As in BASIL-1, these differences were most pronounced after
2 years from index intervention.
Peri-procedural (thirty-day) morbidity in the current series
was very similar to that reported in B1. Thus, in the B1 BS
group, 36% experienced a complication within 30-days and the
majority of these were SSI and other forms of sepsis.
Unlike B1, the current cohort of patients was not rando-
mised and so there will have been selection bias regarding the
choice of revascularization. However, what the data do show is
that, if a patient was deemed fit enough for BS, then long-term
AFS and OS were significantly better than after PBA. This
supports the findings of the BASIL-1 trial overall10 and the
BASIL-1 IP subgroup analysis.8 The unanswered question is
how many patients who underwent PBA in the current cohort
could, and perhaps should, have undergone BS instead; and, if
they had, would they have enjoyed a better longer-term out-
come. Only randomised controlled trials, such as BASIL-2, that
are free of selection basis can address these types of questions.
Use of drug coated balloons and drug eluting stents were
not considered UK standard of care during the time of the study
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as there was no evidence of clinical and, in particular, cost-
effectiveness.6 The UK NICE was criticized for this stance at
the time but, more recently, significant controversy has sur-
rounded the use of such devices owing to meta-analyses11,12
demonstrating an increase in all-cause mortality with paclitaxel
devices. Following the publication of these data, paclitaxel-
based devices were excluded from BASIL-25 and recruitment
was paused in both the BASIL-3 trial13 and SWEDEPAD14
trials. BASIL-3 re-opened in September 2019 and is nearing
the end of recruitment. However, at the time of writing, both
SWEDEPAD registry trials remain closed.
The recently published Global Vascular Guidelines1,2 rec-
ommend an individually tailored approach to revascularization
in patients with CLTI. BS is recommended for infrainguinal
disease in average risk patients with a suitable venous conduit
(expected peri-operative mortality of less than 5% or life
expectancy >2 years). However, these recommendations are
based on the current best available evidence which is cate-
gorised by the GVG writing group as “Level C” (low). Going
forward, it is very important that clinicians offer patients
evidence-based revascularization (EBR) that is both clinically
and, very importantly, given that the greatest future CLTI bur-
den is likely to be in low- and middle-income countries, cost
effective. The results of the BASIL-25, BASIL-313 and BEST-
CLI15 randomized controlled trials are eagerly awaited.
In conclusion, in CLTI patients selected for IP revascular-
ization at our unit, PBA was associated significantly poorer
AFS and OS when compared to BS. This may be explained,
at least in part, by the higher prevalence of diabetes and
ischemic heart disease in this group. However, patients under-
going BS had high peri-procedural morbidity and increased
length of stay. Overall, clinical outcomes in the current cohort
were very similar to those reported in BASIL-1, current
patients undergoing BS fared somewhat better than those
undergoing PBA. Current data support the BASIL-1 IP sub-
group analysis and once again suggest that CLTI patients
requiring revascularization for IP disease should have BS
where possible; and that PBA should usually be reserved for
patients who are not suitable for BS.
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